Reata Pharmaceuticals (NASDAQ:RETA) had its price objective hoisted by research analysts at Robert W. Baird from $162.00 to $245.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has a “positive” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 29.18% from the company’s previous close.
RETA has been the topic of a number of other reports. LADENBURG THALM/SH SH restated a “positive” rating and set a $239.00 target price (up from $133.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, October 16th. BidaskClub upgraded shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 2nd. Zacks Investment Research lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. Citigroup increased their price target on shares of Reata Pharmaceuticals from $194.00 to $241.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, ValuEngine upgraded shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $235.75.
Shares of RETA stock traded up $6.83 during trading hours on Tuesday, reaching $189.66. 17,888 shares of the stock were exchanged, compared to its average volume of 302,527. The business’s fifty day moving average is $146.72 and its two-hundred day moving average is $100.76. Reata Pharmaceuticals has a 12-month low of $47.50 and a 12-month high of $217.47. The firm has a market capitalization of $6.37 billion, a P/E ratio of -66.26 and a beta of 2.75.
In related news, CFO Jason Douglas Wilson sold 4,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $72.68, for a total transaction of $290,720.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James Warren Huff sold 63,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $86.61, for a total value of $5,456,430.00. Following the sale, the chief executive officer now directly owns 164,157 shares of the company’s stock, valued at $14,217,637.77. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,000 shares of company stock worth $10,952,150. Insiders own 34.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Alta Advisers Ltd bought a new stake in shares of Reata Pharmaceuticals in the 3rd quarter valued at approximately $12,897,000. BBVA USA Bancshares Inc. bought a new stake in shares of Reata Pharmaceuticals in the 3rd quarter valued at approximately $321,000. Tower Research Capital LLC TRC increased its holdings in shares of Reata Pharmaceuticals by 1,603.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock valued at $44,000 after acquiring an additional 513 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Reata Pharmaceuticals by 12.2% in the 3rd quarter. First Trust Advisors LP now owns 58,236 shares of the company’s stock valued at $4,676,000 after acquiring an additional 6,319 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Reata Pharmaceuticals in the 3rd quarter valued at approximately $200,000. 58.24% of the stock is owned by hedge funds and other institutional investors.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Story: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.